Evidence map›Paper›PMID 36646795›Full record

ArticleScientific reports2023

Machine learning and metabolic modelling assisted implementation of a novel process analytical technology in cell and gene therapy manufacturing.

Thomas Williams, Kevin Kalinka, Rui Sanches, Greg Blanchard-Emmerson, Samuel Watts, Lee Davies, Carol Knevelman, Laura McCloskey, Peter Jones, Kyriacos Mitrophanous and 2 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Thomas WilliamsOxford Biomedica (UK) Limited, Windrush Court, Transport Way, Oxford, OX4 6LT, UK.
Kevin KalinkaDepartment of Biochemical Engineering, University College London, Bernard Katz Building, Gower Street, London, WC1E 6BT, UK.
Rui SanchesOxford Biomedica (UK) Limited, Windrush Court, Transport Way, Oxford, OX4 6LT, UK.
Greg Blanchard-EmmersonWattBE Innovations Limited, Winchester Business Centre, 10 Parchment Street, Winchester, SO23 8AT, Hampshire, UK.
Samuel WattsWattBE Innovations Limited, Winchester Business Centre, 10 Parchment Street, Winchester, SO23 8AT, Hampshire, UK.
Lee DaviesOxford Biomedica (UK) Limited, Windrush Court, Transport Way, Oxford, OX4 6LT, UK.
Carol KnevelmanOxford Biomedica (UK) Limited, Windrush Court, Transport Way, Oxford, OX4 6LT, UK.
Laura McCloskeyOxford Biomedica (UK) Limited, Windrush Court, Transport Way, Oxford, OX4 6LT, UK.
Peter JonesOxford Biomedica (UK) Limited, Windrush Court, Transport Way, Oxford, OX4 6LT, UK.
Kyriacos MitrophanousOxford Biomedica (UK) Limited, Windrush Court, Transport Way, Oxford, OX4 6LT, UK.
James MiskinOxford Biomedica (UK) Limited, Windrush Court, Transport Way, Oxford, OX4 6LT, UK.
Duygu DikiciogluDepartment of Biochemical Engineering, University College London, Bernard Katz Building, Gower Street, London, WC1E 6BT, UK. d.dikicioglu@ucl.ac.uk.
Oxford BioMedica (United Kingdom) · GBUniversity College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Process analytical technology (PAT) has demonstrated huge potential to enable the development of improved biopharmaceutical manufacturing processes by ensuring the reliable provision of quality products. However, the complexities associated with the manufacture of advanced therapy medicinal products have resulted in a slow adoption of PAT tools into industrial bioprocessing operations, particularly in the manufacture of cell and gene therapy products. Here we describe the applicability of a novel refractometry-based PAT system (Ranger system), which was used to monitor the metabolic activity of HEK293T cell cultures during lentiviral vector (LVV) production processes in real time. The PAT system was able to rapidly identify a relationship between bioreactor pH and culture metabolic activity and this was used to devise a pH operating strategy that resulted in a 1.8-fold increase in metabolic activity compared to an unoptimised bioprocess in a minimal number of bioreactor experiments; this was achieved using both pre-programmed and autonomous pH control strategies. The increased metabolic activity of the cultures, achieved via the implementation of the PAT technology, was not associated with increased LVV production. We employed a metabolic modelling strategy to elucidate the relationship between these bioprocess level events and HEK293T cell metabolism. The modelling showed that culturing of HEK293T cells in a low pH (pH 6.40) environment directly impacted the intracellular maintenance of pH and the intracellular availability of oxygen. We provide evidence that the elevated metabolic activity was a response to cope with the stress associated with low pH to maintain the favourable intracellular conditions, rather than being indicative of a superior active state of the HEK293T cell culture resulting in enhanced LVV production. Forecasting strategies were used to construct data models which identified that the novel PAT system not only had a direct relationship with process pH but also with oxygen availability; the interaction and interdependencies between these two parameters had a direct effect on the responses observed at the bioprocess level. We present data which indicate that process control and intervention using this novel refractometry-based PAT system has the potential to facilitate the fine tuning and rapid optimisation of the production environment and enable adaptive process control for enhanced process performance and robustness.

Indexed as

BioreactorsProteinsCell Culture TechniquesHEK293 CellsHumansMachine LearningProteins

Identifiers

PMID36646795
PMCPMC9842697
OpenAlexW4316469715

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.